Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P S Becker

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Bone Marrow Transplantation|September 15, 2015
A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCTW I Bensinger, P S Becker, T A Gooley, et al.
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
Bone Marrow Transplantation|July 19, 2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantationJ Magenau, P Westervelt, S Khaled, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Bone Marrow Transplantation|September 15, 2015
A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCTW I Bensinger, P S Becker, T A Gooley, et al.
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
Bone Marrow Transplantation|July 19, 2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantationJ Magenau, P Westervelt, S Khaled, et al.
Pageof 6